Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06410313 · ClinicalTrials.gov registry record · NA
First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease
A NA study of Superficial Femoral Artery Stenosis and Popliteal Artery Stenosis, sponsored by Medinol.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 7
- Study locations
NCT06410313: Recruiting NA study of Superficial Femoral Artery Stenosis and Popliteal Artery Stenosis, sponsored by Medinol.
NCT06410313 is a NA study of Superficial Femoral Artery Stenosis and Popliteal Artery Stenosis that is actively recruiting participants, run by Medinol. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06410313, a NA study of Superficial Femoral Artery Stenosis and Popliteal Artery Stenosis, is actively recruiting participants, sponsored by Medinol.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a prospective, open label, multicenter, single arm, first in human clinical study. Patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be enrolled. The patients will be treated with the ChampioNIR Stent System. All implanted patients will be followed up at 30 days and 6, 12, 24 and 36 months. The follow-up visits will include patency evaluation by duplex ultrasound
Primary Outcome
Primary patency of the target lesion defined as the absence of target lesion restenosis (defined by Duplex ultrasound (US) peak systolic velocity ratio (PSVR) ≥2.4).
Conditions Studied
Interventions
- DEVICE ChampioNIR Ridaforolimus Eluting Peripheral Stent System
Study Locations (7)
Other
- The Alfred Hospital - Melbourne
- Royal Perth Hospital - Perth
- Royal North Shore Hospital - Sydney
- Royal Prince Alfred Hospital - Sydney
New York
- Columbia University Medical Center/ NewYork Presbyterian Hospital or CUMC/NYPH - New York
- St Francis Hospital Heart Center - Roslyn
Georgia
- Piedmont Healthcare, Inc. - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-08-15 |
| Est. Completion | 2030-02-28 |
| Phase | NA |
What NCT06410313 shows while recruiting
NCT06410313 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Superficial Femoral Artery Stenosis appearing as the primary indexed condition, and to 1 intervention - of which ChampioNIR Ridaforolimus Eluting Peripheral Stent System is the first listed.
NCT06410313 lists 7 locations in 3 states (Other, New York, Georgia).
Frequently Asked Questions
What is clinical trial NCT06410313 about?
NCT06410313 is a clinical study titled "First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease". This is a prospective, open label, multicenter, single arm, first in human clinical study. Patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be enrolled. The patients will be treated with the ChampioNIR Stent System. All implanted ...
What is the current status of trial NCT06410313?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-08-15. Estimated completion is 2030-02-28.
What conditions does trial NCT06410313 study?
This clinical trial studies the following conditions: Superficial Femoral Artery Stenosis, Popliteal Artery Stenosis.
What interventions are being tested in trial NCT06410313?
The interventions under investigation include: ChampioNIR Ridaforolimus Eluting Peripheral Stent System (DEVICE).
Who is sponsoring clinical trial NCT06410313?
This trial is sponsored by Medinol, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06410313 being conducted?
This trial has 7 study locations across Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Superficial Femoral Artery Stenosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06410313's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI